Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE CYPIONATE versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE CYPIONATE versus TESTRED.
TESTOSTERONE CYPIONATE vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category D/X
Category C
Androgen
Androgen